Trial Profile

Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Ewing's sarcoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
Focus Therapeutic Use
Acronyms CaboMain

Most Recent Events

01 Jul 2024 Planned primary completion date changed from 1 Dec 2025 to 1 Jul 2025.
03 May 2023 Inclusion criteria is updated to remove rhabdoid tumors, Diffuse intrinsic pontine glioma, High grade gliomas, Astrocytoma, Medulloblastoma and Germ Cell tumor. Also metastatic osteosarcoma and ewing sarcoma are specifically included. Planned enrollment number is decreased.
03 May 2023 Planned number of patients changed from 100 to 86.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com